CClinicalTrials.gg
Sign In
Not yet recruitingNCT06059833Updated Sep 29, 2023

Serum Magnesium Level in Type 2 Diabetes Mellitus

An observational study in Diabetes Mellitus, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
30 Years and older
Sex
Female
01

Study summary

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both . Chronic hyperglycemia in synergy with the other metabolic aberrations in patients with diabetes mellitus can cause damage to various organ systems, leading to the development of disabling and life-threatening health complications, most prominent of which are microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications leading to a 2-fold to 4-fold increased risk of cardiovascular diseases Mg2+ deficiency is usually identified by the measurement of serum Mg2+ concentration. Hypomagnesemia is defined by a serum Mg2+ concentration \< 0.75 mmol/L, but a deficiency due to low dietary intake in otherwise healthy people is uncommon. Although overt signs of clinical Mg2+ deficiency are not routinely recognized in the healthy population, relatively low Mg2+ intake and/or Mg2+ status have been shown to be associated with chronic diseases, including cardiovascular disease, T2DM, osteoporosis, pulmonary disease, depression, migraine headaches, inflammation, and cancer

02

Conditions studied

  • Diabetes Mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.

This study's planned enrollment of 120 is below the median of 233 across 2,218 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Sampling method
Probability sample

Study population

Type 2 Diabetes Mellitus according to WHO criteria.

Inclusion criteria

    • Type 2 Diabetes Mellitus according to WHO criteria.

Exclusion criteria

Exclusion Criteria:

    • Renal failure patients.

      • Type I DM patients.
      • Acute pancreatitis.
      • Hyperthyroidism.
      • Hyperparathyroidism.
      • Malignancies.
      • Patients on loop/thiazide diuretics.
      • Patients on Mg supplement.
      • Patients on Mg containing antacids.
      • Any other conditions causing low Mg levels were excluded from the study.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • cases group

    Diagnostic Test: Magnesium

  • control group

    Diagnostic Test: Magnesium

Interventions

  • Diagnostic testMagnesium

    The aim of the study is to evaluate serum Mg level in type 2 DM patients.

06

What researchers measure

Primary outcomes

  1. magnesium perecentage

    evaluate serum Mg level in type 2 DM patients.

    Time frame: 1 year

07

Study locations

1 site
  • Sohag university Hospital
    Sohag, Egypt
    • Magdy M Amin, professor · Contact
08

References and documents

Publications

  • Zheng L, Zhu X, Yang K, Zhu M, Farooqi AA, Kang D, Sun M, Xu Y, Lin X, Feng Y, Liang F, Zhang F, Linhardt RJ. Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043. Polymers (Basel). 2021 Jan 5;13(1):166. doi: 10.3390/polym13010166. PubMed 33466568 ↗
  • Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martin C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PubMed 32872570 ↗
  • Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, Pinotti L, Maier JA, Cazzola R. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021 Jan 22;13(2):320. doi: 10.3390/nu13020320. PubMed 33499378 ↗
  • Feng J, Wang H, Jing Z, Wang Y, Cheng Y, Wang W, Sun W. Role of Magnesium in Type 2 Diabetes Mellitus. Biol Trace Elem Res. 2020 Jul;196(1):74-85. doi: 10.1007/s12011-019-01922-0. Epub 2019 Nov 11. PubMed 31713111 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059833
Lead sponsor
Sohag University
Responsible party
Hasnaa Mohamed Kamel (Resident-clinical pathology department-sohag hospital university, Sohag University) — Principal investigator
First posted
Sep 29, 2023
Start date
Sep 2023 (estimated)
Primary completion
Sep 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Sep 29, 2023

Study contacts

hassnaa M kamel, resident
Contact
hasnaamohamed@med.sohage.edu.eg
01009700227
Elham o Hamd, professor
Contact
01063090309

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus→

Other studies from this sponsor

Sohag University

Start the discussion